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Brain diseases represent a considerable social and economic burden in Europe. With yearly costs of about
800 billion euros and an estimated 179 million people afflicted in 2010, brain diseases are an unquestionable
emergency and a grand challenge for neuroscientists.The Cost of Brain Disorders in
Europe: The Grand Challenge
Brain research is at the forefront of sci-
ence but extensive work is still needed
to understand brain functioning at molec-
ular, cellular, and system levels as well as
to unravel the pathogenesis of complex
brain diseases. Brain research and brain
diseases are relatively new terms. The
former covers neuroscience, neurolog-
ical, and psychiatric research and the
latter includes disorders that might be
classified as neurological or psychiatric,
even though they can be also cared for
by other specialists and general physi-
cians. Both terms are better understood
by decisionmakers and the general public
and were therefore proposed by the
European Brain Council (EBC), an alliance
of all major European organizations inter-
ested in the brain and its diseases. FENS,
the Federation of European Neuroscience
Societies, has been a major supporter
and partner of EBC since its inception
and has participated in a long and suc-
cessful drive to increase the support of
brain research in Europe.
There is no way to escape from the fact
that brain disorders are a major public
health problem in Europe and the rest of
the world. The World Health Organization
(WHO) global burden of disease study and
two major pan-European studies on the
cost of brain disorders were of seminal
importance in disclosing this major chal-
lenge. They demonstrated that, beyond
doubt, brain disorders are the major
public health problem in Europe and all
other high-income countries.
Brain diseases were included in the
global burden of disease study by the
WHO (World Health Organization, 2008;Murray and Lopez, 1997), and the burden
of brain disease was collected in a single
article in 2003 (Olesen and Leonardi,
2003). It showed that brain diseases are
responsible for 35% of Europe’s total dis-
ease burden. This figure was, however,
calculated in terms of so-called DALYs,
or disability-adjusted life years, which is
difficult for politicians and other decision
makers relate to and understand.
In 2003, the EBC decided to fill this
knowledge gap by providing sound esti-
mates of the cost of as many brain disor-
ders as data would allow for all of Europe.
Since data for each disease were only
available in a few countries, a health eco-
nomic model was developed using the
imputation of missing values. The calcula-
tions were based on the cost of a given
disorder in one single person for 1 year
and the 1-year prevalence of the disorder.
More than 100 epidemiology and health
economic experts made the best-
possible estimates from existing data.
Prevalence and cost values were given
as a European mean using all available
national data since no global European
information was available. Values were
then calculated for all European countries
and multiplied with their population to
give the total cost in each single country;
these values were added up to provide
the total European cost. This first cost
study (Andlin-Sobocki et al., 2005) was
prevalence based and it estimated the
cost of a given brain disease for a single
year, namely 2004. It included 12 major
brain disorders, some traditionally classi-
fied as psychiatric, some as neurologic.
Because data were considered too weak
for the inclusion of other brain diseases
at the time, several major disorders wereNeuron 8left out. A major category excluded for
lack of accurate data was represented
by child and adolescent disorders as
well as mental retardation. The document
included both direct and indirect costs
of diseases. Two types of direct costs
were analyzed. All costs related to health
care, such as hospital care, doctor’s
visits, and drugs, regardless of who
pays—the individual, a private insurer,
or the public through taxes and social
insurance—were intended as the direct
health care cost. Costs outside the medi-
cal sector, both private and public, such
as nursing home costs and assistance
given through the municipality to com-
pensate for limitations in function caused
by dementia, multiple sclerosis, or schizo-
phrenia or private costs for adapting to
the disorders, in terms of services or
goods, formed the direct nonmedical
costs. Indirect cost included the days
that can be take off work due to illness,
no matter if this means a short-term
absenteeism from work or early retire-
ment. Presenteeism, intended as limita-
tions in one’s work capability while at
work, was not evaluated as it was consid-
ered too uncertain.
Following this accurate methodology,
the above study already pointed out
that, in 2004, 127 million European citi-
zens were living with a brain disorder,
for a total annual cost of 385 billion euro.
Psychiatric disorders accounted for
62% of the total cost, while the remain-
ing 38% were caused by neurological
diseases including dementia. These data
highlighted that brain disorders were
more costly than cardiovascular dis-
orders or cancer. The results of this study
were made available to the European2, June 18, 2014 ª2014 Elsevier Inc. 1205
Figure 1. Cost of Disorders of the Brain in Europe in 2010
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the European framework program for
research and technological development
(7FP, 2007–2013), and they probably
played a major role in the Commission’s
decision to make brain research one of
the European priorities of FP7.
Given the limitation of the data that
were collected in 2004, EBC committed
a new report, which was published in
2010 (Gustavsson et al., 2011; Olesen
et al., 2012). This new study intended to
present updated, comprehensive, and
accurate estimates of the costs of brain
disorders in 30 European countries with
a population just over 500 million. The
number of disorders for which data were
sufficient for inclusion increased from
12 in the 2004 study to 19 in this new
study (seven disorders were newly con-
sidered, namely specific eating disorders
(anorexia and bulimia nervosa), child
and adolescent disorders, i.e., attention
deficit and hyperkinetic disorders, con-
duct disorders, mental retardation, per-
sonality disorders, sleep disorders, as1206 Neuron 82, June 18, 2014 ª2014 Elseviwell as neuromuscular). Furthermore, a
number of cost items for several dis-
orders, which were missing in the first
study, became available in 2010, making
the cost estimates more complete also
for the previously included diseases. The
methodology of the study was otherwise
the same. One-third of all European citi-
zens—179 million people—had at least
one brain disorder, an astonishing figure
even if many had only minor disorders
such as anxiety or tension-type head-
ache. The total European 2010 cost of
brain disorders was 798 billion euro
per year, of which in average direct
health care costs represent 37%, direct
nonmedical costs 23%, and indirect
costs 40%.
Mood disorders and dementia repre-
sented the most costly diseases for
European society, as demonstrated in
the 2004 study. However, when com-
pared with the latter, these disorders
increased up to 113.4 and 105.2 billion
euros/year, respectively. The new study
showed that the cost per subject with aer Inc.certain brain disorder is highly variable.
For instance, the cost per subject for
brain tumors is 33,900 euros, whereas
the one for migraine is about 662 euros.
Indeed, neuromuscular disorders and
brain tumors are low in terms of pre-
valence but highly costly per patient.
Mood disorders and dementia are both
common and costly. Migraine and anxiety
are highly prevalent but at the same
time the cost per subject is rather low
(Figure 1).
There is a large difference in the distri-
bution of cost categories among the 19
major brain disorders; dementia has the
highest proportion of direct nonmedical
cost (84%), whereas personality disor-
ders and headache have the highest
proportion of indirect costs, 78% and
79%, respectively (Figure 2).
A total amount of 798 billion euros per
year represents a huge amount and
some might fear an exaggeration. On the
one hand, despite all efforts, the so-called
double counting, i.e., counting cost of a
patient with two diseases twice, may not
Figure 2. Relative Direct Health Care, Direct Nonmedical, and Indirect Cost in Europe of 19 Brain Disorders
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there are hundreds of less prevalent brain
disorders that could not be included for
lack of data. Many of them are very costly
per patient and the omission adds up to
a considerable amount that easily offsets
any double counting of included disor-
ders. The cost estimate was thus con-
sidered a relatively conservative one.
A tentative comparison with other major
diseases (although not always possible
or correct due to the limited data avail-
able) indicates that cardiovascular dis-
orders account for 192 billion euro per
year (The European Heart Network,
http://www.ehnheart.org), and the cost
of cancer has been estimated between
150 and 250 billion/year (Wilking et al.,
2006).
Based on these cost data, which were
validated with many other studies on sin-
gle disorders (see, for example, Wimo
et al., 2011 for dementia; Wittchen and
Jacobi, 2005 for addiction; Kleinman
et al., 2003 for bipolar disorders; Kotso-
poulos et al., 2001 for epilepsy; Pelham
et al., 2007 for child disorders), it is clear
that brain diseases are the current andfuture major health economic challenge
for Europe.
The Challenge: How to Change the
Numbers?
Brain disorders can represent a ticking
bomb under Europe’s economy due to
their enormous societal costs, which are
set to growwith the aging of the European
population. Addressing these large costs
for the society requires an intensified
research and novel solutions. To face
this societal emergency, we need to
develop a strong network for both basic
and clinical brain research.
Despite these major challenges and
the efforts of the scientific community in
Europe, we are still struggling against
the discrepancy between the huge socie-
tal impact of brain diseases and the
modest financial and time resources that
are allocated to brain research, teaching,
and care.
Far more research than what we are
currently performing is needed to get
into the causes and developmental path-
ways of brain diseases, for their diag-
nosis, prevention, and treatment.Neuron 8FENS, in collaboration with EBC and its
partners worldwide, supports advocacy
to identify brain research as a priority on
all political agendas, both at national and
international levels. It is our belief that
only a coordinated program to increase
the support to research efforts in the field
can succeed in our ambitious endeavor,
which is to relieve the burden of brain dis-
orders through a better understanding of
the brain. We are strongly convinced
that the promotion of basic research will,
in the future, provide new therapeutic
and diagnostic tools to help patients
with brain-related diseases. It is therefore
FENS’s main goal to promote neurosci-
ence in Europe at all levels, by bringing
together scientists of diverse back-
grounds and by maintaining the engage-
ment of European funding agencies in
supporting basic brain research as well
as research into brain-related diseases.
The EBC effort to estimate burden of
disease and cost of illnesses was and
still is particularly useful in this scenario.
The data from the above-mentioned
studies are often reported and used
in the discussion of priorities, such as2, June 18, 2014 ª2014 Elsevier Inc. 1207
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investments in research and develop-
ment. It is necessary to state that such
priorities are complicated and that other
types of information are important. In our
view, the present data can be exploited
to illuminate key policy decisions, which
include investment in research and
development as the main instrument for
reducing the burden and cost of brain
diseases. It is important for Europe not
only to use existing resources in an effi-
cient and equitable manner, but also
to contribute to the development of
new knowledge to improve the situation.
This is a long-term vision with significant
implications not only for health care but
also for economic development.
But are the previous and current invest-
ments in brain research not sufficient? A
systematic study commissioned by EBC
has provided us with seminal data to
tackle this issue. The study (Sobocki
et al., 2006) estimated both public and
private spending on brain research and
the results were depressing. Comparing
the costs to research funding, brain
research was clearly underfunded. An
attempt was also made to analyze the
possible cost/benefit ratio of increased
investment in brain research and it was
shown to be a highly profitable investment
for society.
How would society benefit from in-
creased funding on brain research? To
answer this question, 200 experts pro-
duced a Consensus document on Euro-
pean brain research, which has been
recently published in its second edition
(Di Luca et al., 2011). The research
needed to fill the gap was discussed un-
der 45 headings in a highly structured
format. Each theme was dealt with by a
multidisciplinary group, consisting of a
basic scientist, a neurologist or a psy-
chiatrist, a patient representative, and a
scientist from industry. Each two-page1208 Neuron 82, June 18, 2014 ª2014 Elsevidescription of a theme ended with a
specific explanation of the benefits to
European society.
Now, the most irrelevant question is:
was all this useful? These efforts have
been extremely successful. The European
Commission provided extensive support
for brain research in FP7. Brain research,
and rightly so, was considered a priority
to be endowed with the necessary, dedi-
cated financial resources. More than two
billion euros have been dedicated to
brain-related research since 2007, with a
yearly allocation of more than 300 million
euros. Such investment supported the
foundation of a novel and active commu-
nity dedicated to brain research, which
has joined forces to reach an unsur-
passed and essential multidisciplinary
effort. We are getting closer to cures,
but we have not got there yet.
The challenge remains and there is the
need to confront it. We can profit from
the already developed highly multidisci-
plinary context, favoring the continuation
of an active research community with
high levels of collaboration and know-
ledge across discipline borders and
respecting a fair balance between basic
and applied research. With the develop-
ment of new working documents of the
European Commission Horizon 2020,
and the start of influential European
programs such as ‘‘The Human Brain
Project’’ FET flagship and complementary
international programs such as the U.S.
Human Brain Initiative, we believe the
intellectual capital on brain research that
was previously seeded can expand and
move forward, hopefully bridging the
gap between knowledge and cure in the
medium-term schedule.
Note: this article reflects presentations
at a Special Interest Event on Global
Advocacy, at the ninth FENS Forum of
Neuroscience in Milan, July 8, 2014,
18:45, where we will discuss the need ofer Inc.advocacy strategies for brain research
in relation to the increasing cost of brain
disease and the negative influence of
the global financial crisis on funding.REFERENCES
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